Clinical trial · Interventional
The Effect of High Dose Simvastatine on Multiple Myeloma
NCT00281476CI-TRIAL-00005706completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the effect of high doses of Simvastatine on bone metabolisme and biochemical markers of disease in Multiple Myeloma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Simvastatine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response estimated by internationally approved criteria after 8 weeks of intermittend treatment with simvastatine
- timeFrame
- 8 weeks after treatment start
Secondary outcomes (2)
- measure
- Changes in markers of bone metabolisme after 8 weeks of intermittend treatment with simvastatine
- timeFrame
- 8 weeks after start of treatment
- measure
- Toxicity according to CTC after 8 weeks of intermittend treatment with simvastatine
- timeFrame
- 8 weeks after start of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * multiple myeloma-patients in need of treatment * stable og progressive disease * age = or \> 18 years * performance status \< 3 * life expectancy \> 3 months Exclusion Criteria: * pregnancy * patients incapable of giving personally concent * renal insufficiens with creatinine clearance below 25 ml/min * alanin aminotransferasis \> 2,5 x upper reference limit * thyroxine below lower reference limit * known familiar muscle-disease ar previous myopati * creatinine kinase \> 10 x upper reference limit * medication with drugs with known interactions wiht simvastatine
References
Publications (0)
Data not yet available
No reference posted for this study.